Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 3.840 +0.070 (+1.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Fate Therapeutics < Previous 1 2 3 4 5 6 7 8 9 Next > Dow Rises Over 300 Points; US Adds 223,000 Jobs In December January 06, 2023 U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 January 06, 2023 Via Benzinga What 6 Analyst Ratings Have To Say About Fate Therapeutics January 05, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session January 06, 2023 Via Benzinga Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday January 06, 2023 Via Benzinga Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket January 06, 2023 Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 06, 2023 The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! Via InvestorPlace Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives January 05, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Cathie Wood Can't Keep Hands Off Tesla As Holiday Season Binge Grows To Nearly Half A Million Shares January 04, 2023 Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million. Via Benzinga Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday January 04, 2023 U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Cathie Wood Loads Up Another $2M In Tesla While Elon Musk Urges Employees To Look Beyond Stock Plunge December 28, 2022 As Tesla Inc (NASDAQ: TSLA) shares witnessed a surprise rebound on Wednesday, Cathie Wood-led ARK Investment Management Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 January 05, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 December 22, 2022 Via Benzinga Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting December 13, 2022 Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models From Fate Therapeutics, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 December 15, 2022 Via Benzinga Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session December 12, 2022 Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. Via Benzinga RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday December 12, 2022 U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 December 12, 2022 From GT Biopharma, Inc. Via GlobeNewswire Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting December 10, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting December 10, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers December 06, 2022 Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Via TheNewswire.com What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers December 06, 2022 By Ernest Dela Aglanu, Benzinga Via News Direct Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors November 07, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at Upcoming Investor Conferences November 04, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress November 03, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting November 03, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Preview: Fate Therapeutics's Earnings November 02, 2022 Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Fate... Via Benzinga What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers October 25, 2022 Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Via Benzinga Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results October 24, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting October 05, 2022 From Fate Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.